Orchard Therapeutics plc Quarterly Debt-to-equity in % from Q3 2019 to Q3 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Orchard Therapeutics plc quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2023.
  • Orchard Therapeutics plc Debt-to-equity for the quarter ending September 30, 2023 was 124 %, a 79.5% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2023 124 +54.8 +79.5% Sep 30, 2023
Q2 2023 109 +49.6 +84.2% Jun 30, 2023
Q1 2023 97.7 +48 +96.6% Mar 31, 2023
Q4 2022 84.5 +42.9 +103% Dec 31, 2022
Q3 2022 68.9 +27 +64.3% Sep 30, 2022
Q2 2022 58.9 +17.9 +43.7% Jun 30, 2022
Q1 2022 49.7 +8.43 +20.4% Mar 31, 2022
Q4 2021 41.6 -0.76 -1.79% Dec 31, 2021
Q3 2021 41.9 +4.93 +13.3% Sep 30, 2021
Q2 2021 41 +9.78 +31.3% Jun 30, 2021
Q1 2021 41.3 +13.6 +49.3% Mar 31, 2021
Q4 2020 42.4 +19 +80.9% Dec 31, 2020
Q3 2020 37 +17.3 +87.4% Sep 30, 2020
Q2 2020 31.2 Jun 30, 2020
Q1 2020 27.6 Mar 31, 2020
Q4 2019 23.4 Dec 31, 2019
Q3 2019 19.7 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.